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ABSTRACT
Selecting the appropriate approach for resection and follow-up of
pheochromocytomas (PCCs) is highly dependent upon reliable local-
ization and exclusion of multifocal, bilateral, or metastatic disease.
Metaiodobenzylguanidine (MIBG) scintigraphy was developed for
functional localization of catecholamine-secreting tissues. Somatosta-
tin receptor imaging (SRI) has a high sensitivity for localizing head
and neck paragangliomas, but studies of intraabdominal PCCs are
rare. In this study we review our experience of [123I]MIBG and SRI,
performed since 1983 and 1989, respectively, in the work-up of pri-
mary and recurrent PCCs. Scintigraphic results were correlated with
catecholamine secretion, size and site, malignancy, associated tumor
syndromes, and morphological features.
[123I]MIBG scans were performed in a total of 75 patients, in 70
cases before resection of primary PCCs and in 5 cases because of
recurrent disease. Ninety-one PCCs were resected. The overall de-
tection rates were 83.3% and 89.8% for PCCs larger than 1.0 cm.
Multifocal disease was detected in 4 patients with [123I]MIBG.
[123I]MIBG uptake correlated with greater size of PCC (r 5 0.33; P 5
0.008) and greater concentration of plasma epinephrine (r 5 0.32; P 5
0.006). [123I]MIBG-negative PCCs (n 5 14) had significantly (P 5
0.01) smaller diameters than [123I]MIBG-positive tumors. Further-
more, [123I]MIBG uptake was significantly higher in unilateral (P 5
0.02), benign (P 5 0.02), sporadic (P 5 0.02), intraadrenal (P 5 0.02),
and capsular invasive (P 5 0.03) PCCs than in bilateral, malignant,
MEN2A/2B-related, extraadrenal, and noninvasive PCCs, respec-
tively. The detection rate of SRI was only 25% (8 of 32) for primary
benign PCCs. In 14 patients metastases occurred, which were effec-
tively visualized with [123I]MIBG in 8 of 14 cases. SRI was able to
detect metastases in 7 of 8 cases, including 3 [123I]MIBG-negative
metastatic cases. In addition, [123I]MIBG and SRI detected 2
recurrences.
In conclusion, [123I]MIBG uptake is correlated with the size, epi-
nephrine production, and site of PCCs. Its role in bilateral and
MEN2A/2B-related PCCs seems limited. In cases of recurrent eleva-
tion of catecholamines, localization of metastases and/or recurrence
should be attempted with [123I]MIBG scintigraphy. In suspicious met-
astatic PCCs, SRI might be considered to supplement [123I]MIBG
scintigraphy. (J Clin Endocrinol Metab 86: 685–693, 2001)
DURING THE LAST 2 decades, management of pheo-chromocytomas (PCCs), catecholamine-secreting tu-
mors arising from chromaffin cells of the sympatho-adrenal
system, has substantially changed. The traditional concept of
proper PCC surgery (1, 2), involving an extensive explor-
atory laparotomy to exclude occult foci in the contralateral
adrenal gland or the retroperitoneal space, has gradually
become a matter of debate (3, 4). With the introduction of less
invasive procedures for resection of PCCs, such as unilateral
approaches through a flank incision (3, 5), laparoscopy (6, 7),
or retroperitoneoscopy (8, 9), accurate preoperative localiza-
tion has become more important. Selecting the appropriate
surgical approach, however, is highly dependent upon re-
liable exclusion of multifocal, bilateral, or metastatic disease.
PCCs can occur in association with several hereditary tumor
syndromes. Gene mutations responsible for Von Hippel-
Lindau disease (VHL) (10) and multiple endocrine neoplasia
type 2A/2B (MEN2A/2B) (11, 12) can be identified, and
detection of carriers of these syndromes has become possible.
Improvements in detection techniques for catecholamines
and emphasis on screening for hereditary cases have in-
creased early stage diagnosis of PCCs and its preceding
medullary hyperplasia. The radiopharmaceutical agent
[131I]metaiodobenzylguanidine ([131I]MIBG), a guanethidine
analog that is stored in sympatho-adrenal tissues, was de-
veloped for adrenal scintigraphy (13, 14). Recently, in a large
European multicenter study, the sensitivity of [131I]MIBG
(n 5 160) to detect PCCs was 81% (4).
Improvements in scintigraphic procedures may reduce
false negative results. Labeling MIBG with 123I instead of 131I
yielded superior imaging quality (15–17). However, 12.5% of
PCCs still remained undetected in the largest published se-
ries to date (n 5 24 PCCs in 120 patients) (18). One could
speculate that structural and functional differences in PCCs
are responsible for diminished [123I]MIBG uptake in different
tumor types. However, potential clinical and morphological
features that could influence [123I]MIBG uptake in PCCs have
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been poorly studied. An alternative approach, somatostatin
receptor imaging (SRI), using [111In-diethylenetriaminopen-
taacetic acid (DTPA)0]octreotide (Octreoscan; Mallinckrodt
Medical B.V., Petten, The Netherlands), was found to have
a sensitivity of over 90% for localizing nonfunctional head
and neck paragangliomas (19, 20). This prompted us to also
use SRI for abdominal PCCs.
In this study we review our experience of preoperative
[123I]MIBG and SRI performed in the diagnostic work-up of
PCC patients. Scintigraphic results were correlated with cat-
echolamine secretion, size and site of the tumors, malig-
nancy, associated tumor syndromes, and morphological fea-
tures of resected PCCs to define subgroups of patients in
whom these scintigraphic techniques might be of use.
Subjects and Methods
Subjects
Between 1983 and 1999 one or more preoperative [123I]MIBG scans
were performed in 70 patients. In 5 additional patients only postoper-
ative [123I]MIBG scans were available because of suspected recurrence.
Patient characteristics are summarized in Table 1. These 75 patients
underwent surgery (or autopsy in 3 patients) for a total of 91 PCCs. In
3 PCC patients, it was decided not to operate, but to palliate with
phenoxybenzamine and a-methyl-paratyrosine, because of great age (in
2 sporadic patients) and widely metastasized medullary thyroid carci-
noma in a MEN2A patient. Autopsy revealed 2 unilateral PCCs in the
sporadic patients and a bilateral PCC in the MEN2A patient. Endoscopic
resection, which has become available in our institute since 1995 (9), was
performed in 11 unilateral and 2 bilateral cases.
Indications for preoperative [123I]MIBG studies included elevation of
basal plasma catecholamines in 65 cases, harboring 76 PCCs. In 5 cases/8
PCCs, basal catecholamine levels were normal, but preoperative
[123I]MIBG scans were performed because of suggestive symptoms in 2
MEN2A cases, 1 MEN2B case, and 2 patients with incidentaloma. Basal
plasma concentrations of norepinephrine (median, 20.44 nmol/L; range,
0.68–151.32; normal, ,3.55 nmol/L), epinephrine (median, 3.62 nmol/L;
range, 0.05–60.45; normal, ,0.55 nmol/L), and dopamine (median, 1.06
nmol/L; range, 0.11–328.53; normal, ,0.65 nmol/L) were measured by
high performance liquid chromatography with electrochemical or flu-
orometric detection (21). Only cases with histologically confirmed in-
traabdominal PCCs were included in this study. The median tumor
diameter of resected PCCs was 4.3 cm (range, ,0.1–15 cm). Resected
adrenal glands of MEN2A/2B cases harboring tumor nodules less than
1 cm, which are usually referred to as (micronodular) medullary hy-
perplasia, were also included in the study group. Malignant PCCs were
defined as metastasized tumors at the time of diagnosis or during follow-
up. Metastases were defined as the presence of tumor at sites where
chromaffin tissue is not normally found.
[123I]MIBG scintigraphy
Whole body (from head to pelvis) planar images or spot views were
obtained 24 h after injection of 370 MBq [123I]MIBG. Spot views of the
upper abdomen were obtained after 48 h. Studies performed in patients
taking labetalol (n 5 3) were excluded from the study. However, 10 days
after labetalol treatment was interrupted, scans were repeated in two of
three patients taking this medicine, and these studies were, therefore,
included. No other agent known to interact with MIBG uptake (sym-
pathicomimetics, adrenergic blocking agents) was taken by any of the
patients. [123I]MIBG studies were subsequently reviewed by the same
experienced investigator (D.J.K.), who was unaware of catecholamine
levels and other clinical information. Uptake intensity was rated ac-
cording to the method described by Mozley and co-workers (18). Uptake
was scored 0 if no uptake was present. Scores of 1, 2, and 3 represent
tumor uptake less than, equal to, and more than reference [123I]MIBG
activity in the liver. These uptake results were correlated with clinical
characteristics, secretion patterns, morphology, and tumor behavior.
SRI
SRI was performed using the commercially available somatostatin
analog [111In-DTPA]d-Phe1-octreotide (Mallinckrodt, Inc., Petten, The
Netherlands). [111In-DTPA]d-Phe-1-octreotide (210–400 MBq) was in-
jected in 28 patients. Planar images were obtained with a double head
or large field of view camera 24 and 48 h after injection. Single photon
emission computed tomography images were available for all patients.
We used a simple yes or no system for definition of tumor visualization.
The two subsequent scans were compared. Any accumulation of radio-
activity at abnormal sites was considered to represent somatostatin
receptor binding if it was visible on both scans.
PCCs
Tumor site (intraadrenal or extraadrenal) and the largest tumor axis
were taken from the pathology reports. Histopathology of primary tu-
mors and metastases was reviewed by one experienced pathologist
(F.T.B.) and served as the gold standard for correlation with imaging
results. Capsular invasion was scored negative if the capsule was intact
or positive when tumor cells, mostly wedge shaped, invaded into or
through the capsule. Vasoinvasion was scored either negative if absent
or positive if invasion into the intratumoral, capsular, or surrounding
vessels was present. In addition, tumor degeneration was scored when
intratumoral necrosis, hemorrhage, or cysts were present.
Statistical analysis
The x2 test was used for comparing nominal variables (categorical
variables without ordering) between groups. For quantifying associa-
tions between variables, Spearman’s nonparametric correlation coeffi-
cient was used. The Mann-Whitney U test (for two groups) was per-
formed to compare ordinal variables (categorical variables with
ordering) or continuous variables that were not normally distributed.
P , 0.05 was considered significant.
Results
Preoperative [123I]MIBG scans
Table 2 summarizes uptake results of 70 preoperative
[123I]MIBG scans. Overall, grade 3 uptake was found in 61 of
84 tumors (72.6%). Uptake equally intense as the activity in
the liver (grade 2) was found in an additional 9 PCCs. There-
fore, if [123I]MIBG uptake equal to or greater than 2 defines
positive detection, the overall detection rate of PCCs of all
sizes was 83.3% (70 of 84). Fourteen PCCs (16.7%) that were
resected in 12 patients, however, had either grade 0 or 1
uptake and therefore remained undetected by [123I]MIBG
scintigraphy. Interestingly, 12 of 14 false negative PCCs ei-
TABLE 1. Patient and tumor characteristics
Feature No.
Patients (male/female) 75 (34/41)
Sporadic 54
MEN2A 11
MEN2B 1
VHL 3
Neurofibromatosis 6
Procedures (unilateral/bilateral) 76 (61/15)
(Thoraco-)laparotomy 55 (43/12)
Flank incision 5 (5/0)
Endoscopic resection 13 (11/2)
Autopsy 3 (2/1)
PCCs (intra-/extraadrenal) 91 (80/11)
Diameter .1 cm 76 (65/11)
Diameter ,1 cm 15 (15/0)
Malignancy 14 patients
Disease free interval [median (range)] 37 months (0–156)
Mortality 9/14
Survival [median (range)] 68 months (0–167)
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ther proved to be malignant (n 5 4 PCCs) or were resected
in early stages from patients with hereditary tumor syn-
dromes (n 5 8 PCCs).
Undetected PCCs had a significantly (P 5 0.01) smaller
tumor diameter (median, 2.9 cm; range, ,0.1 to 14.0 cm) than
those with uptake grade 2 or 3 (median diameter, 4.7 cm;
range, ,0.1 to 15.0 cm). Considering only PCCs with tumor
diameters larger than 1 cm, the detection rate of [123I]MIBG
scintigraphy increased to 89.8% (62 of 69). Of 15 tumors with
diameters less than 1 cm (all but 1 resected from familial
cases), tumor detection was MIBG1/CT1 (computerized to-
mography) in 2 cases, MIBG1/CT2 in 6 cases, MIBG2/CT1
in 5 cases, and MIBG2/CT2 in 2 cases. Therefore, 2 early
staged PCCs from MEN2A and MEN2B patients remained
undetected by all imaging modalities, but were resected any-
way, as bilateral adrenalectomy was routinely performed.
Unexpectedly, carotid body glomus tumors, representing
multifocal disease, were detected on 4 preoperative whole
body [123I]MIBG scans.
Computed tomography (CT) scans were obtained in all
patients and were able to localize 78 of 84 (93%) PCCs. Over-
all, discordant CT/[123I]MIBG localization results were
present in 19 PCCs; i.e. 6 tumors, all smaller than 1 cm,
remained undetected by CT, but were detected by [123I]MIBG
scintigraphy, whereas CT detected 13 tumors not imaged by
[123I]MIBG scintigraphy. There was only 1 presumed false
positive [123I]MIBG localization with grade 3 uptake and
none with grade 2 uptake. This patient, who has VHL syn-
drome, had grade 3 [123I]MIBG hot spots in both adrenal
glands. CT, however, only revealed a unilateral adrenal
mass. Considering the implications of life-long hormonal
replacement in this patient, who was severely neurologically
disabled due to a cerebellar hemangioblastoma, it was de-
cided to resect only the largest adrenal gland. To date, plasma
catecholamine levels remain within the normal range.
Correlation of [123I]MIBG uptake with other
clinical variables
[123I]MIBG uptake was significantly correlated with the
largest diameter of the resected PCCs (r 5 0.33; P 5 0.008).
With regard to functional parameters, only plasma epineph-
rine levels (r 5 0.32; P 5 0.006) showed a significant corre-
lation with [123I]MIBG-uptake (Fig. 1). Plasma norepineph-
rine (r 5 0.09; P 5 0.45), dopamine (r 5 0.13; P 5 0.28), and
urinary levels of vanillylmandelic acid (r 5 0.14; P 5 0.36),
normetanephrine (r 5 0.22; P 5 0.45), and metanephrine (r 5
0.25; P 5 0.37) were not associated with [123I]MIBG uptake.
PCC features and [123I]MIBG uptake (Table 3)
The [123I]MIBG uptake score was significantly lower in the
primary PCCs that subsequently proved to be malignant
than in nonmetastasizing tumors. Furthermore, the
[123I]MIBG uptake score was significantly higher in unilat-
eral, intraadrenal, and sporadic (non-MEN2) tumors than in
bilateral, extraadrenal, and MEN2A/2B-related PCCs. The
microscopic presence of capsular invasion, angioinvasion,
necrosis, or hemorrhage, which was found in 51 of 84, 21 of
84, 30 of 84, and 27 of 84 PCCs, respectively, was not sig-
nificantly correlated with [123I]MIBG uptake.
SRI for benign and malignant PCCs
SRI for localization of the primary tumor or its metastases
was performed in a total of 28 patients before resection of 37
PCCs. In the benign group, only 25% (8 of 32) of the tumors
could be detected with SRI. All of these had been detected
TABLE 3. Statistical comparison of preoperative [123I]MIBG
uptake (n 5 70 preoperative studies) in 84 primary PCCs
performed in 70 patients
Mean [123I]MIBG uptake of
primary PCC
Yes No P valuea
MEN2A/2B (n 5 11/1 patients) 2.00 2.56 0.03
Bilaterality (n 5 13 patients) 2.11 2.57 0.02
Extra-adrenal site (n 5 9 patients) 1.55 2.55 0.02
Malignancy (n 5 9 patients) 1.55 2.51 0.02
Capsular invasion (n 5 51 PCCs) 2.40 2.60 0.18
Angioinvasion (n 5 21 PCCs) 2.76 2.42 0.14
Necrosis (n 5 30 PCCs) 2.28 2.49 0.74
Hemorrhage (n 5 27 PCCs) 2.73 2.49 0.30
a The Mann-Whitney U test was used for statistical comparison of
[123I]MIBG uptake between resected PCCs from patients with clin-
icopathological features.
TABLE 2. [123I]MIBG uptake of 70 scans performed before
resection of 84 PCCs
[123I]MIBG uptake
Pheochromocytomas
Total
Unilateral Bilateral
PCC-side
Grade 3 47/58 (81.0) 14/26 (53.8) 61/84 (72.6)
Grade 2 4/58 (6.9) 5/26 (19.2) 9/84 (10.7)
Grade 1 1/58 (1.7) 3/26 (11.5) 4/84 (4.8)
Grade 0 6/58 (10.3) 4/26 (15.4) 10/84 (11.9)
Unaffected side
Grade 3 1/58 (1.7) 1/58 (1.7)
Grade 2 0/0 (0.0) 0/0 (0.0)
Grade 1 4/58 (6.9) 4/58 (6.9)
Grade 0 53/58 (91.4) 53/58 (91.4)
Percentages are in parentheses.
FIG. 1. Plasma epinephrine levels (note: logarithmic concentrations
are depicted) of PCCs with various [123I]MIBG uptake levels. Median
levels are indicated by horizontal lines.
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with [123I]MIBG scintigraphy. Eighteen benign PCCs that
were negative on SRI were successfully visualized with
[123I]MIBG. Both SRI and [123I]MIBG studies were negative in
6 benign PCCs.
Table 4 summarizes the results of all malignant (patients
1–14) and recurrent (patients 15 and 16) cases. Preopera-
tively, all 5 malignant PCCs were successfully localized with
SRI. Among these 5 malignant PCCs, 2 tumors (patients 10
and 11) were negative with [123I]MIBG scans. Postopera-
tively, in 7 of 8 patients metastases were visualized with SRI.
SRI was significantly more successful in localizing primary
malignant tumors (P 5 0.003) and PCC metastases (P ,
0.0005) than in detecting primary benign PCCs. In all 14
malignant cases 1 or more postoperative [123I]MIBG scans
were performed. The primary indication for scintigraphy in
these was the recurrence of elevated catecholamines after
initial normalization in 8 of 14 cases. In the other 6 cases,
metastases were already present at laparotomy for the pri-
mary tumor. the median disease-free interval was 36.7
months (range, 0–156 months). In 8 malignant cases (cases 1,
3–6, 8, 9, and 13) metastases were effectively visualized with
[123I]MIBG. However in 6 malignant cases (cases 2, 7, 10–12,
and 14), metastases could not be localized by [123I]MIBG, but
in 3 cases they were visualized by SRI (cases 2, 10, and 11).
In all cases with positive SRI and [123I]MIBG, SRI detected
more metastasis sites than [123I]MIBG imaging. Figure 2
shows typical SRI and [123I]MIBG images of metastatic sites
in patient 3. Of interest is patient 7, who was operated upon
because of positive [123I]MIBG and SRI scans indicating an
extraadrenal PCC. Four years later, retroperitoneal metasta-
ses and a nonfunctional recurrence in the same region where
the tumor was formerly resected were detected on a CT scan.
Both [123I]MIBG imaging and SRI were now negative. Diag-
nosis could only be established by fine needle aspiration.
There were two benign recurrences detected by [123I]MIBG
imaging. In case 15, a patient with MEN2A, both adrenal
glands had been resected previously, but PCC still recurred
in remnant adrenal gland tissue. In case 16 a PCC recurred
in the contralateral gland. This patient suffered from Proteus
syndrome, a rare and highly variable congenital hamartoma-
tous condition, comprising asymmetrical overgrowth of dif-
ferent parts of the body. It is characterized by hyperplastic
lesions of connective tissue, vascular malformations, linear
verrucous epidermal nevi, and hyperostoses. This syndrome
has been rarely reported in association with PCC (22).
Discussion
Since the first report in 1979 (13) and the first clinical study
in 1981 (23), [131I]MIBG imaging has been well established as
a localizing tool and a functional marker of catecholamine-
secreting tissue. Initially, most centers used [131I]MIBG as the
PCC-seeking radiopharmaceutical agent. However, shortly
after the publication of promising reports in 1981 (24, 25), we
consistently employed [123I]MIBG scintigraphy in patients
suspected of having PCC. In this large single institutional
series we evaluated the scintigraphic results for localizing
primary tumor sites, multifocal locations, recurrences, and
metastases of 91 intraabdominal, histologically proven
PCCs. In a subset of these patients the use of SRI was ad-
ditionally studied. [123I]MIBG uptake was significantly cor-
related with tumor size and epinephrine production and was
significantly greater in benign, sporadic, intraadrenal, and
unilateral tumors. [123I]MIBG imaging was shown to be com-
plementary to CT. Four multifocal PCC localizations were
detected preoperatively, and metastases were found in 8
patients. SRI was not very helpful as a localizing tool for the
primary tumor. It was, however, useful in detecting metas-
tases, particularly in [123I]MIBG-negative cases.
Anatomical and functional imaging techniques of
primary PCCs
Once the biochemical diagnosis has been made, exact an-
atomical localization of the tumor(s) is mandatory, because
of the variable locations of PCCs. Anatomical localization can
be achieved by CT or magnetic resonance (MR) imaging. CT
scanning is the most widely available and is less expensive;
therefore, as in our hospital, it is the localizing tool of first
choice in most centers (2, 3). Optimal CT imaging of PCCs
consists of pre- and postcontrast thin collimation spiral scan-
ning of the abdomen. Successful detection has been reported
in 80–95% of unilateral PCCs (4, 26). No radiation or iv
contrast media are required in MR studies, which is the
preferred procedure if PCC occurs during pregnancy. Due to
their hypervascularity, PCCs are hyperintense and accu-
rately detected (85–95%) on T2-weighted MR images (4, 26,
27). However, in the light of health care costs, availability,
and investigation time, neither CT nor MR is easily adapted
for imaging of the entire sympatho-adrenal system (from
head to pelvis) for localization or exclusion of extraadrenal
or multifocal PCCs. For this purpose whole body MIBG
scintigraphy serves as a supplement to these anatomical lo-
calization techniques. Therefore, we prefer [123I]MIBG scin-
tigraphy as an initial imaging modality to subsequently di-
rect CT imaging to regions that show increased uptake. In
contrast to CT imaging, MIBG scans are not hampered by
metal clips, which are commonly used during abdominal
surgery. Furthermore, it adds functional information to the
anatomical imaging techniques. As an analog of guanethi-
dine, an adrenergic blocking agent with high affinity for the
adrenal medulla and adrenergic nerves, storage of MIBG
takes place in the catecholamine-containing neurosecretory
granules (27–30). Early studies have validated [131I]MIBG
scintigraphy as a useful localizing technique for intra- and
extraadrenal PCCs, with a high specificity of greater than
95%. However, considerable false negative rates have been
reported, ranging from 13% in studies performed at the Uni-
versity of Michigan (31, 32), to 19% in a large French mul-
ticenter study (4), to almost 25% in other centers in the United
States (33) and Japan (34). This urged us to use [123I]MIBG as
the PCC-seeking radiopharmaceutical agent, because it has
some advantages over [131I]MIBG. Approximately 20 times
higher diagnostic doses can be administered, because of the
shorter half-life of [123I]MIBG and the greater g-camera ef-
ficiency with the 159-keV 123I photon compared with the
364-keV 131I photon used in [123I]MIBG and [131I]MIBG scin-
tigraphies, respectively. This improves photon flux and
yields clearer delineation of tumors (16, 35). Published series
using 123I labeling, however, have been of limited size, at
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least partly due to the fact that [123I]MIBG is not commer-
cially available in the United States (36). In a large series
using [123I]MIBG scintigraphy, uptake was grade 2 or 3 in 22
of 24 (91.7%) of adrenal PCCs (18). In our series this per-
centage was slightly smaller. This may be due to the fact that
31% of PCCs (26 of 84) were resected from patients with
bilateral adrenal disease, whereas in the above-mentioned
series only 1 bilateral PCC was included.
In contrast to our findings, higher frequencies of increased
[123I]MIBG uptake in the normal, nonpathological adrenal
gland have been reported in PCC patients (16, 18). In a
preliminary study by Lynn and co-workers (16) in only 14
patients with PCCs, contralateral visualization of a presum-
ably normal adrenal gland was found in 8 patients. In a study
by Mosley and co-workers (18), visualization of the normal,
nonpathological adrenal gland with [123I]MIBG was found in
5 of 22 (23%) patients using unilateral PCC. However, neither
study provided follow-up data on these scan-positive pa-
tients. Therefore, it cannot be excluded that increased uptake
in otherwise normal adrenal glands might have reflected the
presence of small PCCs or adrenal medullary hyperplasia.
Also, the designs of both studies were different from ours.
The study by Lynn and co-workers (16) was designed to
compare [123I]- and [131I]MIBG scanning in PCCs, and Mos-
ley et al. (18) performed a screening study for PCCs in 120
patients with labile hypertension. Therefore, this latter study
comprised mainly subjects without PCCs (91 of 120 subjects),
whereas all patients had PCCs in our study.
[123I]MIBG scintigraphy in familial and/or bilateral PCCs
As our hospital serves as a tertiary referral center for
endocrine disorders, there is an overrepresentation of he-
reditary, bilateral PCCs. As a result of genetic counseling,
these cases have been referred for surgery at earlier stages
than their sporadic counterparts. Furthermore, we have been
rather liberal in the histopathological designation of the term
PCC. We did not reserve this term solely for macroscopic
tumor nodules (.1 cm), but have also used the term for
microscopic nests of PCC cells. Not surprisingly, the sensi-
tivity of [123I]MIBG scintigraphy was significantly lower in
bilateral and MEN2A/2B-related PCCs. This is in agreement
with the results of other studies, which reported successful
[131I]MIBG detection of bilateral lesions in only 62% of cases
(4). Therefore, referral bias is probably the cause of the sub-
stantially lower detection rate in our series. Although arbi-
trary, others (37) have proposed to differentiate between true
PCC (tumors .1 cm) and nodular medullary hyperplasia
(tumor nodules ,1 cm), which represents the PCC precursor
in the adrenal medulla in MEN2A and MEN2B patients (38)
and sporadic (39, 40) cases. If 1 cm is selected as a cut-off
point for the discrimination between hyperplasia and true
FIG. 2. [123I]MIBG scan (left columns,
anterior and posterior, respectively)
and SRI (right columns, anterior and
posterior) in case 3 (see Table 4). Up-
take of [123I]MIBG is shown in some
metastases, but pathology is found in
more sites (mostly skeletal) with SRI.
Normal uptake in salivary glands, liver,
bowel, and urine bladder is seen with
[123I]MIBG; normal uptake in liver,
spleen, kidneys, bowel, and urine blad-
der is seen with SRI.
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PCC, grade 2 or 3 uptake is found in 89.8% of tumors. This
figure appears to provide the proper perspective on the suc-
cessful detection rate of [123I]MIBG scintigraphy. In the
present study a statistically significant correlation was found
between PCC size and accumulation of [123I]MIBG. This had
already been established for [131I]MIBG scintigraphy (31),
but not for [123I]MIBG (18). For years, our policy in MEN2A/
2B-related PCCs has been bilateral adrenalectomy even in the
presence of a unilateral mass on preoperative imaging. In the
present series 15 adrenal glands were resected for micro-
scopic PCC or medullary hyperplasia, defined according to
the previously mentioned criteria. Seven of these hyperplas-
tic glands, containing only microscopic nests of PCC cells
(so-called Zellballen), remained undetected by [123I]MIBG
scintigraphy. Hence, the role of [123I]MIBG scintigraphy in
early detection of adrenomedullary hyperplasia seems to be
limited. In general, this technique is not advocated if pre-
ventive bilateral adrenalectomy is the therapeutic policy of
first choice in MEN2A/2B patients (41). Considering
MEN2A/2B cases presenting with unilateral adrenal mass,
some experts favor a more conservative policy of unilateral
resection and close follow-up of the contralateral adrenal
gland (42). With the introduction of endoscopic resection,
which is safe and relatively simple and decreases operative
morbidity, we favor this more conservative approach (7, 9).
However, this approach will have important implications for
follow-up investigations. [123I]MIBG may additionally detect
other neuroendocrine tumors, such as medullary thyroid
carcinoma, leading to confusing postoperative scanning re-
sults in multiendocrinopathies such as MEN2A/2B and VHL
(43). Metastases of medullary thyroid carcinoma were more
or less unexpectedly detected in 3 MEN2A patients with
paroxysmal symptoms after bilateral adrenalectomy (data
not shown in Results).
[123I]MIBG uptake in relation to secretory profile of PCCs
We found a significant correlation between epinephrine
plasma levels and [123I]MIBG uptake in the resected tumors.
However, the clinical significance of this finding seems lim-
ited, as there was considerable overlap of plasma epineph-
rine values among the groups (Fig. 1). Others have been
unable to find a proportional correlation between [123I]MIBG
(15, 18) and [131I]MIBG (31, 44) uptake and plasma or urinary
catecholamine levels. [123I]MIBG uptake, however, was
found to be strongly dependent on catecholamine storage
capacity, quantitated by the number of neurosecretory gran-
ules (15). Like norepinephrine, MIBG follows the uptake 1
pathway into these hormone storage vesicles (30). Like others
(45), we have encountered eight cases with only microscopic
PCCs with almost normal catecholamine secretion levels that
showed grade 3 [123I]MIBG uptake. Therefore, MIBG uptake
appears to better represent storage than basal secretion of
catecholamines (15). Compared with patients harboring
small tumors, higher hormone levels may be found in pa-
tients with large tumors; therefore, plasma epinephrine lev-
els may not exhibit an independent predictive value for
[123I]MIBG uptake. However, Eisenhofer and co-workers (46)
were unable to find a correlation between plasma cat-
echolamines and size, as increased metabolism of cat-
echolamines into metanephrines occurs within larger tumors
(through catechol-O-methyltransferase). Moreover, others
have shown that not size but intratumoral hemorrhage and
cystic necrosis are correlated with the paroxysmal release of
stored catecholamines from some PCCs (47). Not surpris-
ingly, these degenerative features are not associated with
increased [123I]MIBG uptake.
SRI for adrenal PCCs
Encouraged by the high sensitivity of SRI in localizing
head and neck paragangliomas (19, 48), we also performed
SRI in a subset of patients with adrenal PCCs. However,
successful detection was only achieved in 25% of the benign
PCCs. As opposed to SRI for head and neck paragangliomas,
imaging of adrenal PCCs seems to be seriously hampered by
physiological uptake in the kidney (20). Therefore, based
upon the present study, performing SRI for localization of
primary PCCs is not advised. Possibly, newer somatostatin
analogs might accumulate more specifically in catechol-
amine-secreting tumors (49, 50).
[123I]MIBG scintigraphy and SRI for ectopic and
malignant PCCs
Up to 20% of PCCs is of extraadrenal origin, which are
frequently multicentric and more likely to be malignant than
those found within the adrenal gland (51). Conflicting data
exist in the literature regarding the usefulness of MIBG scan-
ning of functional extraadrenal PCCs. In agreement with
results from the present study, MIBG uptake has been found
to be significantly less in extraadrenal than in adrenal PCCs
(4, 18). On the other hand, one of the reported advantages of
MIBG whole body studies is its ability to detect multicentric
or metastatic disease, which both occur more frequently in
extraadrenal PCCs (45). Similar to the diminished accumu-
lation in extraadrenal tumors, malignant PCCs also appear
to have less affinity toward [123I]MIBG (51). In 4 of 12 patients
with distant metastases, [123I]MIBG scintigraphy did not vi-
sualize these lesions. For detection of bone metastases, bone
scintigraphy may sometimes be useful (53). In [123I]MIBG-
negative metastases, we and others (29, 54–59) found the role
of SRI to be complementary to that of [123I]MIBG scanning.
In the present series SRI was able to localize 5 of 5 malignant
PCCs and metastases in 7 of 8 patients, including 3 patients
in whom [123I]MIBG scans were negative. These results seem
to indicate that SRI is more sensitive in detecting metastatic
PCCs than in localizing benign tumors (57). In a series of 12
malignant PCCs, 44% of PCC metastases were localized by
SRI (56). Although autoradiographic (60) and immunohis-
tochemical (61) studies have characterized different soma-
tostatin receptor subtypes in PCCs, the therapeutic effects of
octreotide in benign (62) and malignant PCCs (57) have been
disappointing. In our series we have treated 3 patients with
111In-labeled octreotide. All have shown progression of dis-
ease while being treated. Possibly, yttrium-labeled octreotide
(63, 64) might be more useful in these cases.
Beierwaltes and co-workers advocate performing stan-
dard follow-up MIBG investigations after excision of the
primary PCC (65). A routine postoperative MIBG scan might
potentially detect metastatic disease, as it seems likely that
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small deposits of PCC tissue in the near proximity of the main
tumor are not revealed as long as the main tumor is in situ.
In the group of benign tumors we performed 30 postoper-
ative [123I]MIBG scans after resection of the PCCs (data not
shown in Results). In all but 2 cases, postoperative catechol-
amine levels were within the normal range at the time of
imaging. These 2 cases (Table 4: patients 15 and 16) were
subsequently operated upon for PCC recurrence. In addition,
in 1 VHL and 2 neurofibromatosis patients, grade 2 con-
tralateral hot spots were detected after unilateral adrenalec-
tomy. To date, recurrence of increased concentrations of cat-
echolamines has not occurred.
We conclude that the uptake of [123I]MIBG is correlated
with the size and epinephrine production of PCCs. Further-
more, [123I]MIBG uptake is higher in sporadic, benign, in-
traadrenal, and unilateral PCCs, than in hereditary, malig-
nant, extraadrenal, and bilateral PCCs, respectively. For
functional characterization of catecholamine-secreting foci,
whole body [123I]MIBG scintigraphy has a complementary
role to anatomical localization techniques. However, as pa-
tients with familial predisposition are commonly referred
and operated in earlier stages of disease, the role of
[123I]MIBG scintigraphy in bilateral and MEN2A/2B-related
PCCs seems to be limited. In cases of recurrent elevation of
catecholamines, localization of metastases and/or recur-
rence should be attempted with [123I]MIBG scintigraphy. In
suspicious metastatic PCCs, SRI might be considered to sup-
plement [123I]MIBG scintigraphy.
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